Efficacy and safety of insulin degludec/aspart in patients with type 2 and type 1 diabetes mellitus: real-world evidence from Indonesia
IDegAsp demonstrated sustained glycemic improvement at 3-, 6-, and 12-months follow-ups with a favorable safety profile over one year, in both T1DM and T2DM populations in Indonesia. These findings support its utility in routine clinical practice, particularly among patients with unmet glycemic targets or complex treatment needs.
Authors
- Q Iqbal (ORCID: https://orcid.org/0009-0004-9685-7291)
- Hendra Zufry (ORCID: https://orcid.org/0000-0002-0569-4617)
- Agustia Sukri Ekadamayanti
- Krishna Wardhana Sucipto
Institutions
- Universitas Syiah Kuala (ID)
- Universitas Muhammadiyah Aceh (ID)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2025-11-10
- DOI
- https://doi.org/10.3389/fendo.2025.1690169
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Universitas Syiah Kuala